CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Jiri EitlerWiebke RackwitzNatalie WotschelVenugopal GudipatiNivedha Murali ShankarAnastasia SidorenkovaJohannes B HuppaPaola Ortiz-MonteroCorinna OpitzStephan R KünzelSusanne MichenAchim TemmeLiliana Rodrigues LoureiroAnja FeldmannMichael BachmannLaurent BoisselHans KlingemannWinfried S WelsTorsten TonnPublished in: Journal for immunotherapy of cancer (2024)
Downregulation of ICAM-1 on breast cancer cells is a critical escape mechanism from trastuzumab-triggered ADCC. In contrast, CAR-NK cells are able to overcome cancer cell resistance caused by ICAM-1 reduction, highlighting the potential of CAR-NK cells in cancer immunotherapy.